Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures

ObjectiveTo analyze the clinical value of the combination of esketamine and ropivacaine in alleviating rebound pain in patients with upper limb fractures following brachial plexus block.MethodsA total of 149 patients with unilateral upper limb fractures who underwent open reduction and internal fixa...

Full description

Saved in:
Bibliographic Details
Main Authors: Shiyao Zhu, Dan Wang, Haiyan Gao, Lei Heng, Weikang Shui, Shanshan Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Surgery
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fsurg.2024.1470205/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846151728605429760
author Shiyao Zhu
Dan Wang
Haiyan Gao
Lei Heng
Weikang Shui
Shanshan Zhu
author_facet Shiyao Zhu
Dan Wang
Haiyan Gao
Lei Heng
Weikang Shui
Shanshan Zhu
author_sort Shiyao Zhu
collection DOAJ
description ObjectiveTo analyze the clinical value of the combination of esketamine and ropivacaine in alleviating rebound pain in patients with upper limb fractures following brachial plexus block.MethodsA total of 149 patients with unilateral upper limb fractures who underwent open reduction and internal fixation surgery under brachial plexus block anesthesia from November 2021 to August 2022 were selected as the subjects for the study and randomly divided into the esketamine group (RNK group) and the ropivacaine group (R group). The incidence of rebound pain at 48 h postoperatively, intraoperative mean arterial pressure (MAP) and heart rate (HR), the onset time and duration of blockade, the Numeric Rating Scale (NRS) scores for pain at rest and with activity during the perioperative period, the dosage, numbers of compressions, and effective compressions of postoperative patient-controlled analgesia with sufentanil, and occurrence of adverse reactions were assessed and compared between the two groups.ResultsThe incidence of rebound pain in the RNK group was lower than that in the R group (P < 0.05). The RNK group exhibited higher MAP and HR at 5 min and 10 min after anesthesia compared to the R group (P < 0.05). The RNK group had faster onset time and longer duration of sensory and motor blockade compared to the R group (P < 0.05). The NRS scores at rest and with activity at 12 h and 24 h postoperatively in the RNK group were lower than those in the R group (P < 0.05). The total numbers of compressions, effective numbers of compressions, and dosage of sufentanil postoperatively were lower in the RNK group compared to the R group (P < 0.05). The incidence of adverse reactions in the RNK group did not differ significantly from that in the R group (P > 0.05).ConclusionsThe combination of esketamine and ropivacaine demonstrates a favorable preventive effect on rebound pain in patients with upper limb fractures following brachial plexus block, which is conducive to reducing the incidence of rebound pain, shortening the onset time of blockade, and prolonging the duration of blockade.Clinical Trial RegistrationClinicalTrials.gov, identifier (ChiCTR2100053035).
format Article
id doaj-art-ee4e011876e94325881c41a45e68221d
institution Kabale University
issn 2296-875X
language English
publishDate 2024-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Surgery
spelling doaj-art-ee4e011876e94325881c41a45e68221d2024-11-27T06:32:53ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2024-11-011110.3389/fsurg.2024.14702051470205Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fracturesShiyao Zhu0Dan Wang1Haiyan Gao2Lei Heng3Weikang Shui4Shanshan Zhu5Department of Anesthesiology, Xuzhou Cancer Hospital, Xuzhou, ChinaDepartment of Anesthesiology, Xuzhou Cancer Hospital, Xuzhou, ChinaDepartment of Anesthesiology, Xuzhou Cancer Hospital, Xuzhou, ChinaDepartment of Anesthesiology, Xuzhou Cancer Hospital, Xuzhou, ChinaCollege of Anesthesiology, Xuzhou Medical University, Xuzhou, ChinaDepartment of Anesthesiology, Xuzhou Cancer Hospital, Xuzhou, ChinaObjectiveTo analyze the clinical value of the combination of esketamine and ropivacaine in alleviating rebound pain in patients with upper limb fractures following brachial plexus block.MethodsA total of 149 patients with unilateral upper limb fractures who underwent open reduction and internal fixation surgery under brachial plexus block anesthesia from November 2021 to August 2022 were selected as the subjects for the study and randomly divided into the esketamine group (RNK group) and the ropivacaine group (R group). The incidence of rebound pain at 48 h postoperatively, intraoperative mean arterial pressure (MAP) and heart rate (HR), the onset time and duration of blockade, the Numeric Rating Scale (NRS) scores for pain at rest and with activity during the perioperative period, the dosage, numbers of compressions, and effective compressions of postoperative patient-controlled analgesia with sufentanil, and occurrence of adverse reactions were assessed and compared between the two groups.ResultsThe incidence of rebound pain in the RNK group was lower than that in the R group (P < 0.05). The RNK group exhibited higher MAP and HR at 5 min and 10 min after anesthesia compared to the R group (P < 0.05). The RNK group had faster onset time and longer duration of sensory and motor blockade compared to the R group (P < 0.05). The NRS scores at rest and with activity at 12 h and 24 h postoperatively in the RNK group were lower than those in the R group (P < 0.05). The total numbers of compressions, effective numbers of compressions, and dosage of sufentanil postoperatively were lower in the RNK group compared to the R group (P < 0.05). The incidence of adverse reactions in the RNK group did not differ significantly from that in the R group (P > 0.05).ConclusionsThe combination of esketamine and ropivacaine demonstrates a favorable preventive effect on rebound pain in patients with upper limb fractures following brachial plexus block, which is conducive to reducing the incidence of rebound pain, shortening the onset time of blockade, and prolonging the duration of blockade.Clinical Trial RegistrationClinicalTrials.gov, identifier (ChiCTR2100053035).https://www.frontiersin.org/articles/10.3389/fsurg.2024.1470205/fullbrachial plexus blockesketaminerebound painropivacaineupper limb fractures
spellingShingle Shiyao Zhu
Dan Wang
Haiyan Gao
Lei Heng
Weikang Shui
Shanshan Zhu
Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures
Frontiers in Surgery
brachial plexus block
esketamine
rebound pain
ropivacaine
upper limb fractures
title Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures
title_full Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures
title_fullStr Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures
title_full_unstemmed Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures
title_short Clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures
title_sort clinical value of esketamine combined with ropivacaine in rebound pain after brachial plexus block in patients with upper limb fractures
topic brachial plexus block
esketamine
rebound pain
ropivacaine
upper limb fractures
url https://www.frontiersin.org/articles/10.3389/fsurg.2024.1470205/full
work_keys_str_mv AT shiyaozhu clinicalvalueofesketaminecombinedwithropivacaineinreboundpainafterbrachialplexusblockinpatientswithupperlimbfractures
AT danwang clinicalvalueofesketaminecombinedwithropivacaineinreboundpainafterbrachialplexusblockinpatientswithupperlimbfractures
AT haiyangao clinicalvalueofesketaminecombinedwithropivacaineinreboundpainafterbrachialplexusblockinpatientswithupperlimbfractures
AT leiheng clinicalvalueofesketaminecombinedwithropivacaineinreboundpainafterbrachialplexusblockinpatientswithupperlimbfractures
AT weikangshui clinicalvalueofesketaminecombinedwithropivacaineinreboundpainafterbrachialplexusblockinpatientswithupperlimbfractures
AT shanshanzhu clinicalvalueofesketaminecombinedwithropivacaineinreboundpainafterbrachialplexusblockinpatientswithupperlimbfractures